创新药全线爆发！港股创新药ETF（513120）盘中成交额突破65亿元，创历史新高

Group 1 - The core viewpoint of the articles highlights the strong performance of the innovative drug sector in both A-share and Hong Kong markets, driven by policy support and market expectations for industry upgrades and technological breakthroughs [1][2]. - The Hong Kong Innovative Drug ETF (513120) has seen a year-to-date increase of over 50%, indicating significant market interest and investment in the innovative drug sector [1]. - Recent policy enhancements in medical insurance and the acceleration of the internationalization of domestic innovative drugs have contributed to the sustained growth and optimism in the industry [1][2]. Group 2 - The market is shifting towards growth sectors, with innovative drugs being a key focus due to their combination of policy support and technological barriers [2]. - The Hong Kong Innovative Drug ETF (513120) and the Innovative Drug ETF (515120) provide investors with convenient tools to invest in high-quality innovative drug companies in their respective markets [2]. - The pharmaceutical sector has experienced a prolonged adjustment period, resulting in relatively low overall valuations, which may lead to a recovery in the market [2]. Group 3 - The Hong Kong Innovative Drug ETF (513120) has a scale of 99 billion, with an average daily trading volume exceeding 23 billion, making it the top performer in its category [3]. - The year-to-date increase for the Hong Kong Innovative Drug ETF is 48.60%, while the A-share Innovative Drug ETF has increased by 13.80% [3]. - The driving factors for the sector include valuation recovery and the strengthening of domestic alternatives, with a projected improvement in payment conditions under supportive policies for commercial insurance development [3].